Merck highlighted evidence of a rising response rate to its closely watched immunotherapy MK-3475, spotlighting an 81% overall survival rate for advanced melanoma patients after 12 months of therapy with 41% of all patients demonstrating tumor shrinkage--rising to an impressive 51% for one group at the high end of the dose range.
With Gilead's pioneering hepatitis C drug sofosbuvir moving closer to a likely approval and a megablockbuster market, AbbVie is looming from behind with some promising results from the first of 6 Phase III studies of its breakthrough triple-threat therapy.
Promising results from early-stage work on Zafgen's weight drug beloranib clear a path to a Phase IIb trial that can fine-tune the dose while taking more time to gauge the long-term impact of its treatment on weight and set the right tone for ongoing talks with investors about a new financing round for the biotech.
The reemergence of H7N9 in China during the past month has reinforced the need for a vaccine. Candidates from Chinese and Taiwanese manufacturers have grabbed the headlines recently, but now a U.S. player, Novavax, has joined the race with positive Phase I data.
Theravance CEO Rick Winningham put out the word today that its drug TD-9855 flunked a mid-stage study for attention deficit/hyperactivity disorder, adding that the biotech planned to scrap the program while continuing a separate study for fibromyalgia.
Two months after merging with ReSearch Pharmaceutical Services to form the world's fourth-largest CRO, PRA is back on the buyer's block, snatching up the early-stage-focused CRI Lifetree.
Your dominant hand may be an indicator of your predisposition to certain psychotic disorders, such as schizophrenia, according to a new study by Yale researchers.
The pharma giant reported that the drug did not produce a statistically significant improvement in the risk of heart attack, stroke or death, though it added that "greater reductions" for some of the secondary endpoints warranted careful follow-up review as investigators considered its potential.
Agenus and a Sanofi-NIH collaboration both gave updates on their genital herpes vaccine candidates this week. The Agenus vaccine, HerpV, is leading the race, having met its primary endpoint in a Phase II trial of 80 subjects, 70 of whom received the treatment.
A little more than a year since its last lead therapy bit the dust, Zalicus today reported that its new lead drug foundered in a pair of mid-stage studies and will join the company's growing scrap heap. The news triggered a rout on Wall Street, with shares in meltdown mode after the news hit.